Cisplatin versus Other Platinum Combined with Etoposide in Treatment of Small Cell Lung Cancer: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 TANGHong-mei ¹ ,  TUXing ^1,2 , XIONGFen ¹ , LUOQian ¹ , SUFen-li ¹ , SUZhi-qiang ¹ , ZHANGQing-ye ¹ , CAIQing-qun ¹

1. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China;
2. Guangzhou University of Chinese Medicine, Guangzhou 510405, China;

Corresponding?author：

TUXing, Email: kuangsheng1234@126.com

Keywords：

Cisplatin; EP regimen; Small cell lung cancer; Meta-analysis; Systematic review; Randomized controlled trial

DOI：

10.7507/1672-2531.20150075

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of cisplatin combined with etoposide versus other platinum combined with etoposide in the treatment of small cell lung cancer (SCLC). Methods We searched PubMed, The Cochrane Library (Issue 8, 2013), MEDLINE (Ovid), CNKI, VIP and WanFang Data to collect randomized controlled trials (RCTs) concerning the efficacy and safety of cisplatin combined with etoposide (the cisplatin group) versus other platinum combined with etoposide (the control group) for SCLC. The search was up to August 2013. Two reviewers screened literatures according to the inclusion and exclusion criteria, extracted data and assessed the methodological quality of included studies. And then, meta-analysis was performed by using RevMan 5.2 software. Results A total of 6 RCTs involving 684 patients were included. The results of meta-analysis showed that there were no significant differences in disease control rate (DCR) (RR=1.03, 95%CI 0.91 to 1.17, P=0.63), overall response rate (ORR) (RR=1.04, 95%CI 0.97 to 1.11, P=0.33), occurrence of leukocytopenia (RR=0.97, 95%CI 0.81 to 1.17, P=0.77), decreased hemoglobin (RR=0.89, 95%CI 0.61 to 1.31, P=0.56) between the cisplatin group and the control group. Occurrence of thrombocytopenia was lower (RR=0.49, 95%CI 0.38 to 0.63, P<0.000 01) while occurrence of nausea and vomiting was higher (RR=1.80, 95%CI 1.40 to 2.31, P<0.000 01) in the cisplatin group. Conclusion Current evidence shows that the clinical efficacy of cisplatin combined with etoposide for SCLC is equal to other platinum combined with etoposide, but it has a certain advantage in decreasing the aggregative rate of platelets, while the gastrointesnial reaction patients should avoid using cisplatin combined with etoposide.

Citation： TANGHong-mei, TUXing, XIONGFen, LUOQian, SUFen-li, SUZhi-qiang, ZHANGQing-ye, CAIQing-qun. Cisplatin versus Other Platinum Combined with Etoposide in Treatment of Small Cell Lung Cancer: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2015, 15(4): 452-457. doi: 10.7507/1672-2531.20150075 Copy

1.	胡義德, 錢桂生. 小細胞肺癌綜合治療:實踐指南. 中華肺部疾病雜志(電子版), 2011, 4(5):356-359.
2.	曹子昂. 2014第一版NCCN小細胞肺癌治療指南解讀. 中國前沿醫學雜志(電子版), 2013, 5(12):79-81.
3.	張笑辰, 張麗錦, 鄒蘊, 等. 順鉑及順鉑載體的研究進展. 中國當代醫藥, 2011, 18(22):25-26.
4.	唐棣華. 抗癌藥物順鉑抗癌機制的線索. 化學研究與應用, 2010, (1):96.
5.	Edge SB, Byrd DR, Compton CC, et al. American joint committee on cancer (AJCC) cancer staging manual. 7^th ed. Chicago:Spring, Inc, 2009:103-115.
6.	鄧可剛. 循證醫學證據的檢索步驟與檢索系統的選擇. 中國循證醫學雜志, 2004, 4(9):634-637.
7.	羅杰, 冷衛東. 系統評價/Meta分析理論與實踐. 北京:軍事醫學科學出版社, 2013:76.
8.	李然, 王睿, 湯建華, 等. 紫杉醇治療小細胞肺癌的系統評價. 中國循證醫學雜志, 2008, 8(10):851-860.
9.	Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase Ⅲ trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer:JCGO 9702. Br J Cancer, 2007, 97(2):162-169.
10.	齊曉倩, 魏長宏, 武貴存, 等. 洛鉑、順鉑分別聯合足葉乙苷治療老年小細胞肺癌對照研究. 武警后勤學院學報, 2012, 21(4):258-262.
11.	于清清, 王明玉. 洛鉑或順鉑聯合依托泊苷治療初治小細胞肺癌臨床療效的觀察. 腫瘤藥, 2013, 3(2):107-110.
12.	Guo W, Liao G, Gao H, et al. Randomized comparison of lobaplatin plus etoposide and cisplatin plus etoposide chemotherapy in patients with extensive-stage small cell lung cancer. Chinese-German J Clin Oncol, 2013, 12(8):365-368.
13.	Karam I, Jiang SY, Khaira M, et al. Outcomes of small cell lung cancer patients treated withcisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol, 2013, 38(1):51-54.
14.	陳天君, 高飛, 孫忠民, 等. 依托泊苷聯合洛鉑或順鉑治療廣泛期小細胞肺癌的對照研究. 西安交通大學學報(醫學版), 2013, 24(2):198-201.
15.	Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol, 2003, 30(1):9-25.
16.	趙艷萌, 高麗萍, 郭卓雨. 順鉑誘發腎毒性機制的研究進展. 廣東醫學, 2013, 34(23):3679-3681.
17.	鄭日葵. 順鉑同步放療在肺癌治療中的毒性分析和劑量控制. 海峽藥學, 2013, 25(2):66-67.
18.	于大連, 亓衛東, 張梅, 等. 順鉑及其耳毒性. 中國耳科學雜志, 2008, 6(2):125-133.
19.	王金全, 姚林. 順鉑所致的周圍神經毒性及其防治措施. 中國新藥雜志, 2005, 14(10):1236-1239.
20.	閆長會, 施暢, 李玉鳳, 等. 新鉑類藥物雙環鉑與順鉑、卡鉑體內毒性的比較研究. 中國新藥雜志, 2005, 14(10):1156-1159.
21.	鄧建浩, 史道華. 鉑類藥物神經毒性的藥物基因組學研究進展. 中國臨床藥理學與治療學, 2012, 17(4):458-462.

1. 胡義德, 錢桂生. 小細胞肺癌綜合治療:實踐指南. 中華肺部疾病雜志(電子版), 2011, 4(5):356-359.
2. 曹子昂. 2014第一版NCCN小細胞肺癌治療指南解讀. 中國前沿醫學雜志(電子版), 2013, 5(12):79-81.
3. 張笑辰, 張麗錦, 鄒蘊, 等. 順鉑及順鉑載體的研究進展. 中國當代醫藥, 2011, 18(22):25-26.
4. 唐棣華. 抗癌藥物順鉑抗癌機制的線索. 化學研究與應用, 2010, (1):96.
5. Edge SB, Byrd DR, Compton CC, et al. American joint committee on cancer (AJCC) cancer staging manual. 7^th ed. Chicago:Spring, Inc, 2009:103-115.
6. 鄧可剛. 循證醫學證據的檢索步驟與檢索系統的選擇. 中國循證醫學雜志, 2004, 4(9):634-637.
7. 羅杰, 冷衛東. 系統評價/Meta分析理論與實踐. 北京:軍事醫學科學出版社, 2013:76.
8. 李然, 王睿, 湯建華, 等. 紫杉醇治療小細胞肺癌的系統評價. 中國循證醫學雜志, 2008, 8(10):851-860.
9. Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase Ⅲ trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer:JCGO 9702. Br J Cancer, 2007, 97(2):162-169.
10. 齊曉倩, 魏長宏, 武貴存, 等. 洛鉑、順鉑分別聯合足葉乙苷治療老年小細胞肺癌對照研究. 武警后勤學院學報, 2012, 21(4):258-262.
11. 于清清, 王明玉. 洛鉑或順鉑聯合依托泊苷治療初治小細胞肺癌臨床療效的觀察. 腫瘤藥, 2013, 3(2):107-110.
12. Guo W, Liao G, Gao H, et al. Randomized comparison of lobaplatin plus etoposide and cisplatin plus etoposide chemotherapy in patients with extensive-stage small cell lung cancer. Chinese-German J Clin Oncol, 2013, 12(8):365-368.
13. Karam I, Jiang SY, Khaira M, et al. Outcomes of small cell lung cancer patients treated withcisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol, 2013, 38(1):51-54.
14. 陳天君, 高飛, 孫忠民, 等. 依托泊苷聯合洛鉑或順鉑治療廣泛期小細胞肺癌的對照研究. 西安交通大學學報(醫學版), 2013, 24(2):198-201.
15. Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol, 2003, 30(1):9-25.
16. 趙艷萌, 高麗萍, 郭卓雨. 順鉑誘發腎毒性機制的研究進展. 廣東醫學, 2013, 34(23):3679-3681.
17. 鄭日葵. 順鉑同步放療在肺癌治療中的毒性分析和劑量控制. 海峽藥學, 2013, 25(2):66-67.
18. 于大連, 亓衛東, 張梅, 等. 順鉑及其耳毒性. 中國耳科學雜志, 2008, 6(2):125-133.
19. 王金全, 姚林. 順鉑所致的周圍神經毒性及其防治措施. 中國新藥雜志, 2005, 14(10):1236-1239.
20. 閆長會, 施暢, 李玉鳳, 等. 新鉑類藥物雙環鉑與順鉑、卡鉑體內毒性的比較研究. 中國新藥雜志, 2005, 14(10):1156-1159.
21. 鄧建浩, 史道華. 鉑類藥物神經毒性的藥物基因組學研究進展. 中國臨床藥理學與治療學, 2012, 17(4):458-462.

Chinese Journal of Evidence-Based Medicine

Cisplatin versus Other Platinum Combined with Etoposide in Treatment of Small Cell Lung Cancer: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content